PL8177 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
PL8177 is Palatin's peptide pill that switches on MC1R, for ulcerative colitis. In a small mid-stage study, 33 percent went into remission against 0 percent on a dummy pill, before the study was cut short.
Evidence grade for PL8177: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 2 human studies where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
2 human studies where nobody was given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
PL8177 is a peptide pill from Palatin for ulcerative colitis. It switches on MC1R in the gut to calm inflammation. It does not shut down the immune system. It is not approved.
What people take it for
- Putting ulcerative colitis into remission.
- Calming gut inflammation without shutting down the immune system.
What studies in people showed
The study stopped at 12 people when Palatin went looking for a partner. A third of people on the drug went into remission. Nobody on a dummy pill did. About three quarters improved, against a third on the dummy. No side effects were reported. With twelve people, one or two people move every one of those numbers.
What people report
Reports, not study results
The good
- In the tiny study on this page, a third of people went into remission.
The bad
- The study was cut short at 12 people, far too few to trust.
Where these come from: Both lines are from the company release and study record on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Twelve people is a reason to run a real study. If you have colitis, stay with your gut doctor.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is PL8177?
PL8177 is Palatin's peptide pill that switches on MC1R, for ulcerative colitis. In a small mid-stage study, 33 percent went into remission against 0 percent on a dummy pill, before the study was cut short.
PL8177 is a ring-shaped peptide that switches on MC1R. It is built to act in the gut and settle inflammation, rather than shut down the immune system. The mid-stage study in ulcerative colitis stopped at 12 people when Palatin went looking for a partner. It reported remission in 33 percent against 0 percent on a dummy pill, and improvement in 78 percent against 33 percent, with no side effects. The numbers look good, but the study is far too small to prove anything. Palatin's separate pill for obesity, PL7737, which targets MC4R, had early results expected in 2026.
How does PL8177 work?
It switches on MC1R on immune cells and the gut lining, which helps inflammation settle down.
The evidence, in charts
Fig. 1a · how many people
12people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Palatin press release 2025 | 12 | 100% |
The whole total is one study of 12. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2025.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- 996.1 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for PL8177, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025Palatin announces positive topline results from Phase 2 ulcerative colitis study of PL8177
The result looks striking and the study is far too small to mean much. Twelve people with ulcerative colitis took PL8177 or a dummy pill. A third of those on the drug went into remission and none on the dummy did, and about three quarters improved against a third. No side effects were reported. Here is the problem. With twelve people, one or two individuals move every percentage you just read. This is a reason to run a proper trial, not a result.
Remission 33% versus 0% in 12 patients.
- Study in people2025PL8177 Phase 2 in ulcerative colitis
The trial was stopped before it could answer anything. Palatin halted enrolment while looking for a partner to take the drug on, which left too few people in the study to spot a difference even if there was one. The numbers that exist come from twelve participants. A study cut short for business reasons is not evidence that a drug works, and it is not evidence that it fails.
Stopped early for out-licensing; underpowered.
Where to buy PL8177
No seller we track lists PL8177 yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has PL8177 been tested in people?
Not in a completed trial cited here. 2 human studies where nobody was given it. PL8177 is Palatin's peptide pill that switches on MC1R, for ulcerative colitis. In a small mid-stage study, 33 percent went into remission against 0 percent on a dummy pill, before the study was cut short.
What is the PL8177 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 2 human studies where nobody was given it
Is PL8177 FDA-approved?
Investigational; in mid-stage studies
Is PL8177 related to PT-141?
Both come from Palatin and both act on melanocortin receptors. PT-141 targets MC4R for sexual function. PL8177 targets MC1R for gut inflammation.
Latest reading on PL8177
Blog posts about PL8177, newest first.